Arbutus Biopharma (ABUS) Shares Outstanding (Weighted Average) (2010 - 2026)

Arbutus Biopharma has disclosed Shares Outstanding (Weighted Average) across 17 years of filings, most recently posting $193.8 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $193.8 million, up 1.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $193.8 million (up 1.61% YoY), and the FY2025 annual result was $191.6 million, up 3.23% from the prior year.
• Shares Outstanding (Weighted Average) came in at $193.8 million for Q1 2026 at Arbutus Biopharma, up from $191.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $193.8 million in Q1 2026 to a low of $148.4 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $175.6 million (2024), against an average of $173.7 million.
• Across the five-year window, Shares Outstanding (Weighted Average) soared 58.86% in 2022 and rose 1.61% in 2026, its largest moves.
• Arbutus Biopharma's Shares Outstanding (Weighted Average) stood at $150.9 million in 2022, then increased by 9.95% to $166.0 million in 2023, then rose by 11.84% to $185.6 million in 2024, then grew by 3.23% to $191.6 million in 2025, then increased by 1.13% to $193.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $193.8 million (Q1 2026), $191.6 million (Q4 2025), and $191.3 million (Q3 2025), per Business Quant data.